Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Active not recruiting 2Suspended 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 490Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 422Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

talazoparib 1olaparib 1Pluvicto 1Lutetium-177 1Lutetium 1CX 5461 1BAY 2315497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT07621692 2026-06-02

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

National Taiwan University Hospital

Phase 1 Recruiting
12 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03724747 2024-11-08

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Bayer

Phase 1 Completed
63 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05425862 2023-12-11

REPAIR

Peter MacCallum Cancer Centre, Australia

Phase 1 Suspended
48 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡